LDS/Medical Tests/Human Immunodeficiency Virus 1 (HIV-1) RNA, Qualitative or Quantitative

Human Immunodeficiency Virus 1 (HIV-1) RNA, Qualitative or Quantitative

The Human Immunodeficiency virus type-1 (HIV-1) is a retrovirus that causes HIV disease and AIDS. Worldwide, there are over 33 million people infected. In the US, the Centers for Disease Control and Prevention (CDC) estimates that there are over a million HIV infected individuals, with one in five not knowing they are infected. Approximately 18,000 individuals die from HIV-related illnesses in the US each year.

The most common modes of HIV infection are through infected needles, sexual contact, and from mother to infant. Individuals were previously infected through blood and blood products; however, universal screening of the blood supply for the presence of this virus has stopped this mode of transmission. Once infected, the primary infection may be symptomatic, with patients developing flu-like symptoms; or asymptomatic, where patients do not realize they have been infected. After the primary infection, the body never is able to totally eliminate the virus and a long-term (chronic) infection ensues. Chronic infection results in depletion of the cells that fight infection, leaving the patient susceptible to a wide range of opportunistic organisms. It is infection with these organisms that ultimately prove detrimental to the patient.

There are two types of Human Immunodeficiency viruse, HIV-1 and HIV-2. HIV-1 is more common; HIV-2 is mainly in isolated areas of Africa. Both are similar in their mode of action. HIV infects and destroys a specific type of white blood cell (WBC), called a CD4 lymphocyte that is a major part of the body’s immune system. It is the subsequent depletion of these cells that results in the immune system becoming compromised, thus the term “immunocompromised.” Once the immune system is compromised, the body is susceptible to infections. Thus, the goal of HIV therapy is to keep the level of circulating virus low and the level of CD4 cells high.

The HIV-1 viral load assay is used to determine the level of circulating virus in the patient’s blood. The assay detects HIV-1 RNA in plasma or serum by reverse transcriptase PCR (RT-PCR) or branched DNA (bDNA) technology. It is approved for patients previously diagnosed with HIV-1 infection using another method (it is not approved as a diagnostic assay). It is used for assessing the baseline viral load in HIV-1 positive patients prior to the initiation of anti-retroviral therapy, and for monitoring viral RNA levels throughout the course of infection and in response to anti-retroviral therapy. Changes in the levels of HIV-1 RNA during treatment may be helpful in early detection of potential therapeutic failure due to the emergence of a resistant virus and/or disease progression. Changes in viral load levels of at least 2 logs typically indicate the treatment is working, while changes in viral load levels less than 2 logs may indicate treatment failure. The HIV-1 viral load level, however, is not a sole indicator of disease progression or severity. It should be used in conjunction with other clinical markers and laboratory tests such as CD4 counts.

  • Diagnosis and management of persons infected with HIV-1
  • Management of persons with AIDS
  • Monitoring therapy treatment

Positive in HIV infected patients, usually >1,000,000 viral copies in acute phase. Levels decrease to A 3-fold (0.5 log10) change in HIV-1 RNA viral load is a significant medical indicator for treatment and management of HIV infection.

Increasing levels may be due to disease progression or failed antiretroviral therapy. Increase viral load might be also related to other co-infections such as tuberculosis, pneumococcal pneumonia, yeast infection or others.

Decreasing levels indicate therapeutic response and improved clinical outcome.

In patients beginning treatment, persistent HIV RNA viremia at levels >200 copies/mL for more than 24 weeks indicates treatment failure.

Patients with virologic failure (confirmed viral load >200 copies/mL) should be tested for antiretroviral drug resistance, which can be used to modify the treatment regimen.

Not Detected (Negative)

Real-time Polymerase Chain Reaction (PCR), Transcription Mediated Amplification (TMA), other molecular methods.

Plasma EDTA (Lavender) or PPT (White). 

Stability

  • Ambient: Unacceptable
  • Refrigerated: 48 hours
  • Frozen: 60 days
CD4 Count, CD4/CD8 Count, HIV genotyping, HIV Phenotyping, CMV, HSV, EBV, Bacterial and Yeast Culture.

1-3 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Curr HIV/AIDS Rep. 2012 Jan 4. [PMID: 22215419]
  • New Microbiol. 2010 Jan;33(1):1-11. [PMID: 20402409]
  • JAMA. 2008 Aug 6;300(5):555-70. [PMID: 18677028]
  • Expert Rev Mol Diagn. 2007 May;7(3):237-46. [PMID: 17489731]
  • Curr Pharm Des. 2006;12(9):1045-63. [PMID: 16515485]
  • MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207. [PMID: 19357635]
  • Lennette EH, Smith TF (editors): Laboratory Diagnosis of Viral Infections, 3rd ed. Marcel Dekker (1999).
  • Murray PR et al (editors): Manual of Clinical Microbiology, 8th ed. ASM Press (2003).
  • Guidelines for the use of HIV-1 RNA levels in clinical practice have been published [(17); http://www.aidsinfo. nih.gov, http://www.iasusa.org].